Morecroft Renee, Phillipps Jordan, Zhou Alice, Butt Omar, Khaddour Karam, Johanns Tanner, Ansstas George
Division of Medical Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, United States.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Front Oncol. 2024 May 8;14:1385094. doi: 10.3389/fonc.2024.1385094. eCollection 2024.
Immunotherapy is the first-line option for treating advanced cutaneous squamous cell carcinoma (cSCC). However, up to half of patients experience no benefit and treatment resistance, warranting newer therapeutic approaches. Combinatory approaches, including cetuximab, may help overcome immunotherapy resistance and improve response rates in advanced cSCC. We report three cases of metastatic cSCC that achieved significant clinical responses after cetuximab therapy following initial progression on pembrolizumab. We have retrospectively reviewed these cases at a single academic center between 2018 and 2023. All patients initially progressed on pembrolizumab, after which cetuximab (mono- or combination therapy) was added with two complete responses and one partial response. Initial responses were noted within 2 to 7 months of starting cetuximab. While the benefit of cetuximab and immunotherapy in head-and-neck squamous cell carcinoma has growing evidence, information regarding cSCC remains limited. This study adds three cases to the underreported literature on treating advanced cSCC with cetuximab after initially failing immunotherapy.
免疫疗法是治疗晚期皮肤鳞状细胞癌（cSCC）的一线选择。然而，高达一半的患者没有获益且出现治疗抵抗，这就需要更新的治疗方法。包括西妥昔单抗在内的联合治疗方法可能有助于克服免疫疗法抵抗并提高晚期cSCC的缓解率。我们报告了3例转移性cSCC病例，这些病例在帕博利珠单抗初始治疗进展后接受西妥昔单抗治疗后取得了显著的临床缓解。我们在2018年至2023年期间在一个学术中心对这些病例进行了回顾性分析。所有患者最初在帕博利珠单抗治疗时出现进展，之后加用西妥昔单抗（单药或联合治疗），出现了2例完全缓解和1例部分缓解。在开始使用西妥昔单抗后的2至7个月内观察到初始缓解。虽然西妥昔单抗和免疫疗法在头颈部鳞状细胞癌中的获益证据越来越多，但关于cSCC的信息仍然有限。本研究为免疫疗法初始失败后用西妥昔单抗治疗晚期cSCC的报道不足的文献增加了3个病例。
